Aptorum Group Limited (APM.PA)

2.7 €

0.00 (-%)
Rating:
Recommendation:
-
Symbol APM.PA
Price 2.7 €
Beta 0.000
Volume Avg. -
Market Cap 74.287M
Shares () -
52 Week Range 2.7-2.7
1y Target Est -
DCF Unlevered APM.PA DCF ->
DCF Levered APM.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 36.96% Neutral
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
Paris

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.